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Geﬁtinib and erlotinib, which are epidermal growth factor receptor- (EGFR-) speciﬁc tyrosine kinase inhibitors (TKIs), are widely
used as molecularly targeted drugs for non-small-cell lung cancer (NSCLC). Currently, the search for EGFR gene mutations is
becoming essential for the treatment of NSCLC since these have been identiﬁed as predictive factors for drug sensitivity. On
the other hand, in almost all patients responsive to EGFR-TKIs, acquired resistance is a major clinical problem. Mechanisms of
acquired resistance reported in the past few years include secondary mutation of the EGFR gene, ampliﬁcation of the MET gene,
andoverexpressionofHGF;novelpharmaceuticalagentsarecurrentlybeingdevelopedtoovercomeresistance.Thisreviewfocuses
on these mechanisms of acquired resistance to EGFR-TKIs and discusses how they can be overcome.
1.Introduction
Theepidermalgrowthfactorreceptor-(EGFR-)speciﬁctyro-
sine kinase inhibitors (TKIs) geﬁtinib and erlotinib are
molecularly targeted drugs used for the treatment of non-
small-cell lung cancer (NSCLC). In clinical trials, although
response rates were approximately 10%–19%, in some cases
dramatic responses have been observed soon after initiation
of treatment, with this trend being particularly strong in
Japanese patients, women, nonsmokers, and adenocarci-
noma cases [1, 2]. In 2004, three research groups reported
that the existence of the activating mutations of EGFR gene
was a predictive factor for sensitivity to EGFR-TKIs [3–5].
Deletion mutations, mainly occurring around codons 746–
750 in exon 19, and the substitution of leucine with arginine
at codon 858 in exon 21 (L858R) comprise approximately
90% of these mutations [6]. These mutations are more
prevalent in Asians, women, non smokers, and patients with
adenocarcinoma, groups that match the highly geﬁtinib-
sensitiveclinicalsubset[6].Manyinvestigatorshavereported
results from retrospective analyses of associations between
EGFR gene mutations and EGFR-TKI sensitivity. These
analyses indicate that approximately 70%–80% of mutation-
positive cases are EGFR-TKI sensitive whereas in wild-type
patients the response rate is 10%–20% [6].
In recent years, three important ﬁndings have been repo-
rted regarding EGFR gene mutations and geﬁtinib treatment
by Asian groups. First, in the IPASS trial, geﬁtinib treatment
was compared with carboplatin and paclitaxel combination
therapy in untreated East Asian patients with advanced pul-
monary adenocarcinoma who were non-smokers or former
light smokers [7]. The geﬁtinib group had a longer prog-
ression-free survival (PFS) than the carboplatin–paclitaxel
groupamongallpatientgroups(hazardratioforprogression
ordeath,0.74).Inthesubgroupofpatientswhowerepositive
for EGFR gene mutations, PFS was signiﬁcantly longer
among those who received geﬁtinib than among those who
received carboplatin–paclitaxel therapy (9.5 months versus
6.6 months). Additionally, two Japanese groups reported the
results of Phase 3 comparative clinical trials of geﬁtinib treat-
ment and combined platinum-based treatment for EGFR
gene mutation-positive patients. Both the WJTOG3405 [8]2 Journal of Biomedicine and Biotechnology
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Figure 1: Mechanism of acquired resistance to EGFR-TKI (modiﬁed from reviews of Mitsudomi and Yataba [6] and Yano [13]). (a) Survival
signal through the PI3K/Akt pathway in NSCLC cells with an EGFR activating mutation (star). (b) EGFR-TKI inhibits phosphorylation of
EGFR and the survival signal is shut down, leading to apoptosis of cells. (c) Secondary T790M mutation prevents binding of EGFR-TKI to
EGFR, resulting in cell survival. (d) Ampliﬁed MET causes phosphorylation of ERBB3. Even when phosphorylation of EGFR is inhibited by
EGFR-TKI, activation of the PI3K/Akt pathway is maintained through ERBB3. (e) HGF induces activation of the PI3K/Akt pathway through
MET; this activation is independent of ERBB3 or EGFR.
and NE J002 trials [9] showed better PFS for the geﬁtinib
group (9.2 months versus 6.3 months and 10.4 months
versus 5.5 months, resp.).
Although EGFR-TKI treatment shows good response
r a t e sa n dP F Si nN S C L Cp a t i e n t sw i t hEGFR gene mutations
as mentioned above, acquired resistance to EGFR-TKI treat-
mentalmostalwaysdevelopsafteramedianofapproximately
10 months from the initiation of treatment. To date, several
major mechanisms of acquired resistance, such as secondary
mutation of the EGFR gene, ampliﬁcation of the MET gene,
andoverexpressionofHGF,havebeenreportedandadvances
inthedevelopmentofeﬀectivepharmaceuticalagentsagainst
these mechanisms are being made. EGFR gene mutations
suchasexon20insertions[10,11]andKRASgenemutations
[12] are believed to contribute to primary resistance to
EGFR-TKI treatment. This review focuses on recent ﬁndings
regarding the mechanisms of acquired resistance after initial
response to EGFR-TKI therapy and discusses how they can
be overcome.
2.AcquiredResistance
2.1. Secondary T790M Mutation of the EGFR Gene
2.1.1. About the Secondary T790M Mutation. A secondary
mutation of the EGFR gene reported in 2005 was the
ﬁrst mechanism of acquired resistance to EGFR-TKIs to be
identiﬁed [14–16]. When threonine-to-methionine muta-
tions in codon 790 (T790M) in exon 20 of the EGFR gene
occur additively as a secondary mutation, drug resistance is
observed despite the occurrence of drug-sensitive activating
mutations (Figure 1(c)). Crystal structure modeling has
revealed that T790 is located in the ATP-binding pocket
of the catalytic region and appears to be critical for the
binding of erlotinib and geﬁtinib. T790 is often referred to
as the “gatekeeper residue.” Substitution of the threonine
at this codon with a bulkier residue, such as methionine,
is believed to sterically hinder the binding of these drugs.
This amino acid change is not expected to interfere with
ATP binding and, therefore, is not expected to alter the
activity of the kinase on ligand stimulation [14]. A recent
analysis showed that T790M mutations do not considerably
aﬀect the binding aﬃnity between EGFR and EGFR-TKIs
but instead increase the binding aﬃnity between EGFR and
ATP, causing a relative decrease in binding with EGFR-
TKIs [17]. The authors reported that increased ATP aﬃnity
is the primary mechanism by which the T790M mutation
confers drug resistance. An experiment using cell lines
transfected concurrently with activating mutations and a
T790M mutation also proved that resistance to geﬁtinib and
erlotinib is evident when this mutation is present [14–16].
Analogous secondary mutations of the BCR-ABL gene
in case of chronic myelogenous leukemia (CML) [18]a n d
the KIT gene in case of gastrointestinal stromal tumor [19]
have previously been reported as mechanisms of imatinib
resistance, which is also a TKI. The structural similarity
between ABL and EGFR tyrosine kinases is considerably
high, and T315I in ABL corresponds to T790M in EGFR
[20]. Using BaF3 cells, Azam et al. revealed that a gatekeeper
threonine mutation stabilizes an active conformation of
these tyrosine kinases through a network of hydrophobic
interactions known as the hydrophobic spine and has a
transforming function [21].The authors anticipated that this
regulatory mechanism would be conserved across the kinase
family.
In summary, from the above three reports and subse-
quent reports on T790 mutations using clinical specimens
from patients with acquired resistance to EGFR-TKIs [22–
24], a secondary T790M mutation has been detected in
approximately 50% of all patients.Journal of Biomedicine and Biotechnology 3
2.1.2. Occurrence of T790M Mutations. Interestingly, T790M
mutations exist as minor clones in almost all reported cases
of acquired resistance. In every case, the results of sequence
analysis or subcloning analysis indicate that the T790M
mutant alleles or clones were lesser in number than wild-
type alleles or clones. To address this issue, Inukai et al.
proposed a clonal selection model of T790M mutant cells
[25]. They used a highly sensitive method, that is, a mutant-
enriched PCR assay to analyze clinical specimens from 280
sample cases who were not treated with geﬁtinib, and they
detected 9 cases (3.6%) with a 790M mutation. Mutation
was detected by direct sequencing in only one of the 9 cases;
therefore the fraction of T790M mutant cells may have been
considerably small. Inukai et al. hypothesized that geﬁtinib
treatment may lead to the selection of T790M mutant cells
and that even a small fraction of T790M-positive tumor cells
at the beginning of treatment could lead to clinical geﬁtinib
resistancebecauseofselectiveproliferationofT790Mmutant
cells. Maheswaran et al. proved this hypothesis by analyzing
circulating tumor cells using a highly sensitive method [26].
They analyzed pretreatment tumor samples from 26 NSCLC
cases with activating EGFR gene mutations and found low
levelsofT790Min10ofthesecases(38%).Becausedetection
of T790M required a relatively high number of ampliﬁcation
cycles, the T790M mutation has been inferred to be present
in only few cells. When PFS was analyzed among these 26
cases after administering EGFR-TKI, the PFS for cases with
T790M mutations during pretreatment was signiﬁcantly
shortercomparedtothatforcaseswithoutT790Mmutations
(median 7.7 months versus 16.5 months, P<. 01). Given
these results, the researchers inferred that the T790 mutant
cells that existed as minor clones might be selected during
treatment and become dominant after treatment.
This is analogous to the mechanism used by certain
secondary mutations of the ABL genes in CML [27, 28]. Pre-
existing small fractions of mutations become major clones
when the tumor becomes resistant to imatinib, probably
because of the selection pressure due to imatinib treatment
[28].
Although rare, T790M mutations exist as major clones
irrespective of geﬁtinib administration in certain patients
[29, 30]. T790M mutations have also been reported to exist
as germline mutations in families with a history of high
incidence of familial lung cancer [31]. Vikis et al. reported
that standalone T790M mutations exhibit increased kinase
activity. Furthermore, the human bronchial epithelial cell
line that transfects T790M mutations has a higher growth
advantage than wild-type cells, although not as high as
that of deletion mutations [32]. Mulloy et al. showed
that the T790M mutant exhibits tyrosine phosphorylation
levels comparable to those of wild-type EGFR, whereas the
T790M/L858R double mutant exhibits a substantial increase
in phosphorylation compared with the L858R mutant alone
[33]. Godin-Heymann et al. also reported similar phenom-
ena for both L858R mutations and a deletion mutation of
exon 19, and discussed combination of activating mutations
and T790M mutations is important to oncogenic perfor-
mance [34]. Maheswaran et al. proposed that T790M may
initially arise because of these oncogenic characteristics and
may rapidly emerge as a dominant allele after treatment
[26].
2.2. MET Gene Ampliﬁcation. In 2007, a research group at
the Dana-Farber Cancer Institute reported that MET gene
ampliﬁcation is involved in acquired resistance to geﬁtinib
[24]. The MET gene encodes a transmembrane tyrosine
kinase receptor that acts as an HGF receptor and is involved
with invasion, metastasis, and angiogenesis in tumors. The
authors established geﬁtinib-resistant clones from a sensitive
cell line with EGFR exon 19 deletion mutations (HCC827)
byexposingthecellstoincreasingconcentrationsofgeﬁtinib.
In these resistant cells, T790M mutations were not observed
butMET geneampliﬁcationoccurred.METcausesphospho-
rylation of ERBB3, which in turn sustains the activation of
the phosphatidylinositol 3-kinase (PI3K)/Akt signal down-
stream. Because of these phenomena, even with geﬁtinib
inhibiting the phosphorylation of ERBB3 by EGFR, the pro-
liferation signal is not inhibited because of the maintenance
of the phosphorylation of ERBB3 by MET, which causes
the cells to become resistant to geﬁtinib (Figure 1(d)). Con-
versely,whentheMETsignalwassuppressedinresistantcells
that were dependent on MET ampliﬁcation, sensitivity to
geﬁtinib was clearly restored. In the analysis of clinical speci-
mens from 18 cases of acquired resistance, MET gene ampli-
ﬁcation was observed in 4 cases (22%), and T790M muta-
tions were present in 10 of 18 cases, more than half as many
as were expected. The coexistence of MET geneampliﬁcation
and a T790M mutation was reported in one of these cases.
Bean et al. also focused on MET gene ampliﬁcation
by comparing genomic proﬁles of EGFR mutant tumors
from untreated patients with those from patients with
acquired resistance using array-based comparative genomic
hybridization[35].Inananalysisof43patientswithacquired
resistance, MET gene ampliﬁcation was observed in 9 cases
(21%). In addition, 4 of the 10 tumors with MET gene
ampliﬁcation had a T790M mutation. These results indicate
that MET gene ampliﬁcation and T790M mutation may
possiblyoccurindependently.Combiningbothreports,MET
gene ampliﬁcation is shown to be present in approximately
20% cases of acquired resistance.
MET gene ampliﬁcation in cases not treated with EGFR-
is said to occur with a frequency in the range of a few percent
in all reports [35–38]b a ro n e[ 39], where it was reported
to be approximately 20%. This leads one to think of the
possibility that the few cells that have undergone MET gene
ampliﬁcation before treatment become major clones after
EGFR-TKI treatment, similar to the previously described
occurrence of T790M mutations. Turke et al. performed an
analysis of lung cancer patients and cell lines using the high-
throughput FISH method and identiﬁed a subpopulation of
cellswithMET geneampliﬁcationbeforedrugexposure[40].
Particularly in the HCC827 cell line, they discovered that
thesubpopulationwithpre-existing MET geneampliﬁcation
was rapidly selected when hepatocyte growth factor (HGF)
was administered along with EGFR-TKI. In analysis of
clinical specimens having acquired resistance, MET gene
ampliﬁcation was observed in 4 out of 27 cases (15%)
(T790Mmutationswereobservedin15cases,55%).Analysis4 Journal of Biomedicine and Biotechnology
of the pretreatment specimens from those 4 cases indicated
that the subpopulation with MET gene ampliﬁcation was
very small, less than 1% of the entire population. This proves
that clonal selection occurs in the mechanism of MET gene
ampliﬁcation, as with the T790M mutation.
2.3. Overexpression of HGF. In 2008, a Japanese research
group reported that overexpression of HGF, a speciﬁc ligand
of MET, is involved in EGFR-TKI resistance [41]. They
administered HGF to human adenocarcinoma cell lines that
harbored EGFR exon 19 deletion mutations and showed
that HGF induces resistance to geﬁtinib in a dose-dependent
manner.Furthermore,byanalyzingintracellularsignaltrans-
mission pathways, HGF was shown to induce restoration of
the PI3K/Akt signaling pathway through phosphorylation of
MET. Interestingly, although MET gene ampliﬁcation acti-
vates downstream signals by associating with ERBB3, HGF
induces downstream signal activation through MET; this
activation is independent of ERBB3 or EGFR (Figure 1(e)).
Analysis using clinical specimens also showed cases of high
HGF expression among acquired resistance cases that did
not have a T790M mutation or MET ampliﬁcation as well as
among cases that exhibited primary resistance despite having
EGFR-TKI sensitive activating EGFR gene mutations.
Turke et al. reported similar results [40]. They analyzed
27acquiredresistancecasesandfoundthatinthe16casesfor
which pre- and posttreatment specimen pairs were available,
HGFexpressionwassigniﬁcantlyhigherinthedrug-resistant
specimens than in the pretreatment specimens. They also
found that in the 11 cases where only the specimens
postresistance acquisition were available, HGF expression
values were high and similar in value to those of the
postresistance acquisition specimens in the paired cases. In
addition to inducing EGFR-TKI standalone resistance, Yano
et al. [41] found that HGF induced drug resistance by selec-
tive proliferation of clones with MET gene ampliﬁcation.
Although the frequency of HGF expression among cases of
acquired resistance is unclear because of scarcity of reports,
the frequency of coexistence of HGF expression with T790M
mutations could possibly be high [42].
2.4. Other Mechanisms of Acquired Resistance
2.4.1. Other Secondary EGFR Gene Mutations. Other sec-
ondary EGFR gene mutations such as D761Y [22], L747S
[43], and T854A [44] mutations have been reported. How-
ever, the frequency of all such mutations appears to be low in
comparison with the T790M mutation and further analysis
of such cases is required in the future.
2.4.2. IGF-1R. Guix et al. established geﬁtinib-resistant
clones from a geﬁtinib-sensitive cell line of squamous cell
lung carcinoma that ampliﬁed the wild-type EGFR gene
(A431) by exposing the cells to increasing concentrations
of geﬁtinib [45]. In the geﬁtinib-resistant cell line, hyper-
phosphorylation of the insulin-like growth factor-1 (IGF-1)
receptor (IGF-1R) was observed instead of suppressed
EGFR, and the PI3K/Akt signal was activated through IGF-
1R. Gene expression analysis showed a considerably reduced
expression of IGF-binding protein 3 and IGF-binding
protein 4 RNA, which are known to inhibit IGF-induced
activation of IGF-1R. As these analyses were performed
using cell lines, results from studies conducted using clinical
specimens are now required for further understanding.
3. Strategies to Overcome AcquiredResistance
3.1. Irreversible EGFR Inhibitor. Geﬁtinib and erlotinib are
reversible EGFR-TKIs, also known as ﬁrst generation EGFR-
TKIs. In contrast, the drugs currently being developed
to overcome resistance are second generation EGFR-TKIs,
typiﬁed by irreversible EGFR-TKIs. Unlike reversible EGFR-
TKIs, irreversible EGFR-TKIs covalently and irreversibly
bind a cysteine residue in EGFR to the amino acid position
797 [16]. This enables them to inhibit EGFR kinase activity
even in the presence of an EGFR T790M mutation. Many
of these irreversible inhibitors have demonstrated activity
in preclinical studies against T790M mutations. HKI-272
[46, 47] and BIBW 2992 [48, 49], which are dual inhibitors
against EGFR and HER2, and PF-00299804 [50], which
is a multi-inhibitor against EGFR, HER2, and HER4, are
representative agents currently undergoing clinical trial.
On the other hand, these irreversible EGFR-TKIs have
yet to meet expectations in terms of clinical eﬀectiveness.
All current EGFR inhibitors possess a structurally related
quinazoline-based core scaﬀold and are identiﬁed as ATP-
competitive inhibitors of wild-type EGFR. One eﬃcacy
limiting factor is believed to be the dosage limitation
imposed by the toxicity because of concurrent inhibition of
wild-type EGFR [46]. Zhou et al. screened an irreversible
kinaseinhibitorlibraryspeciﬁcallyagainstEGFRT790Mand
identiﬁed a covalent pyrimidine EGFR inhibitor [51]. These
agentsare30-to100-foldmorepotentagainstEGFRT790M,
and up to 100-fold less potent against wild-type EGFR,
than quinazoline-based EGFR inhibitors in vitro. These
mutant-selective irreversible EGFR-TKIs could be clinically
more eﬀective and better tolerated than quinazoline-based
inhibitors. The results of clinical application of these agents
are expected.
Cell lines resistant to irreversible EGFR-TKIs have been
established using methods similar to those used for estab-
lishing reversible EGFR-TKI-resistant cell lines. Using these
cell lines, the mechanisms of acquired resistance have been
revealed. Ercan et al. established a resistant cell line for
an irreversible EGFR-TKI by subjecting a reversible EGFR-
TKI resistant cell line with a T790M mutation (established
by long-term exposure of exon 19 deletion mutant PC9
cells to geﬁtinib) to long-term exposure to PF-00299804
[52]. In the geﬁtinib-resistant cell line, clones with ampliﬁed
T790M mutant alleles existed in small quantities. Selective
proliferation of these clones occurred on long-term exposure
to PF-00299804. The researchers suggested that although
irreversible EGFR-TKI may be transiently eﬀective against
cancers harboring T790M mutations, clones harboring
ampliﬁed EGFR T790M will rapidly emerge in vitro and
in vivo through selection of pre-existing EGFR T790M or
high-expressing clones, leading to clinical drug resistance.
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for MET gene ampliﬁcation [40]. In another study, Yamada
et al. reported that HGF overexpression is involved not
only with acquired resistance against reversible EGFR-TKIs
but also with acquired resistance against irreversible EGFR-
TKIs [53]. In the future, reports of further studies using
clinical specimens can be expected, possibly leading to the
development of pharmaceutical agents to overcome these
mechanisms.
3.2. MET Inhibitors and HGF Inhibitors. The eﬃcacy of
inhibitors of MET gene ampliﬁcation and HGF overexpres-
sion was revealed in a preclinical study. For MET gene
ampliﬁcation, the MET inhibitor PHA-665752 [24] and, for
HGF overexpression, HGF-MET inhibitors, such as anti-
HGF antibodies and the HGF-antagonist NK4, have been
reported to be eﬀective [54].
Establishment of resistant cell lines and the mechanism
of acquired resistance against MET inhibitors have also been
reported. McDermott et al. established such a cell line by
continuously exposing EBC-1, an NSCLC cell line with MET
ampliﬁcation, to a MET inhibitor, PF2341066 [55]. In the
PF2341066-resistant cell line, the EGFR signal pathways
were activated. Resistance was suppressed by the combined
application of PF2341066 and erlotinib.
MET gene ampliﬁcation and HGF overexpression often
overlap with T790M mutations. To prevent acquired resis-
tance, combined use of an irreversible EGFR-TKI and MET
inhibitors is being studied. Although tolerability issues may
arise, the outlook appears promising.
4. Conclusion
Today, EGFR-TKIs are known to contribute considerably to
the extension of PFS in prognosis for NSCLC. We predict
that understanding and overcoming EGFR-TKI resistance
mechanisms will lead to further extensions and we look
forward to reviewing future analyses.
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